Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors.
OBJECTIVE
We investigated whether the insertion/deletion (I/D) polymorphism of the ACE gene modified the adherence to ACE inhibitors as measured by the discontinuation of an ACE inhibitor, or addition of another antihypertensive drug.


METHODS
This was a cohort study among 239 subjects who started ACE inhibitor therapy. A Cox proportional hazard model was used to calculate relative risk (RR).


RESULTS
During follow-up there was no significant difference between subjects with the DD, ID or II genotype (DD vs II; RR = 1.17, 95%CI: 0.78, 1.77 and ID vs II; RR = 1.06, 95%CI: 0.73, 1.55) in adherence.


CONCLUSIONS
The I/D polymorphism of the ACE gene does not influence the adherence to ACE inhibitors.
Schelleman
H
H
Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
Klungel
O H
OH
van Duijn
C M
CM
Witteman
J C M
JC
Hofman
A
A
de Boer
A
A
Stricker
B H Ch
BH
D000368:Aged; D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004251:DNA Transposable Elements / Q000235:genetics*; D017353:Gene Deletion; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000235:genetics; D008875:Middle Aged; D010349:Patient Compliance; D016133:Polymerase Chain Reaction / Q000379:methods; D011110:Polymorphism, Genetic / Q000235:genetics*; D011446:Prospective Studies; D018570:Risk Assessment
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004251:DNA Transposable Elements